Key Highlights

  • PAVmed (NASDAQ:PAVM) climbed 9.95% to USD 2.10, ahead of a November 13, 2026 Business update call.
  • Hain Celestial Group (NASDAQ:HAIN) rose 9.62% to USD 0.1470, in advance of November 9, 2026 earnings.
  • Zhengye Biotechnology (NASDAQ:ZYBT) slipped 7.52% to USD 1.23 with no announcement identified.
  • Cheche Group (NASDAQ:CCG) gained 11.73% to USD 8.00, with first-half net revenues down 34.4%.
  • SurgePays (NASDAQ:SURG) advanced 8.57% to USD 0.1672, with cash of USD 1,954,235 at June 30, 2026.

PAVmed (NASDAQ:PAVM) (up USD 0.1900, 9.95%): A Call Notice Alongside Limited Cash

PAVmed (NASDAQ:PAVM) rose 9.95% to USD 2.10 in pre-market trading on November 3, 2026. No announcement explaining the jump was identified for November 2 or November 3. The latest release, dated October 30, 2026, only scheduled its Third Quarter 2026 business update call for November 13, 2026 at 8:30 AM ET and contained no financial results.

Second quarter 2026 Revenue was USD 33 thousand, with a net loss attributable to common stockholders of about USD 5.5 million. Cash was USD 3.8 million at June 30, 2026 against six-month operating expenses of USD 15.1 million, so cash covers roughly one quarter of spending at the first-half pace (calculated). As a penny stock, it carries volatility, thin Liquidity and dilution risk.

Hain Celestial Group (NASDAQ:HAIN) (up USD 0.0129, 9.62%): A Pre-Earnings Move in a Sub-Dollar Share

Hain Celestial Group (NASDAQ:HAIN) rose 9.62% to USD 0.1470 in pre-market trading on November 3, 2026. No announcement tied directly to the move was identified. On November 2, 2026 the company said it will report fiscal 2027 first quarter results on November 9, 2026, so the gain may reflect pre-earnings positioning.

Nasdaq granted a second compliance period through March 22, 2027 for the USD 1.00 minimum bid price rule, and the company said a Reverse Stock Split is possible. Fiscal 2026 net sales were USD 1,353 million, down 13%, with a net loss of USD 305 million. Total Debt was USD 558 million, and a lender extension of the December Maturity was still being pursued.

Zhengye Biotechnology (NASDAQ:ZYBT) (down USD 0.1000, 7.52%): Light Trading and a Lower Price

Zhengye Biotechnology (NASDAQ:ZYBT) slipped 7.52% to USD 1.23 in pre-market trading on November 3, 2026, implying a prior close of about USD 1.33 (calculated). No company press release, filing or Earnings report dated October 30 to November 3, 2026 was identified. As a penny stock, it can swing sharply on limited liquidity.

On July 21, 2026, after a surge in price and volume, the company said it was not aware of any material non-public information behind the activity. The Jilin-based veterinary Vaccine maker offers 50 vaccines and markets its products in 29 Chinese provincial regions. It received a Nasdaq minimum bid price notice on May 29, 2026 and later announced it had regained compliance, but the cushion above USD 1.00 is thin.

Cheche Group (NASDAQ:CCG) (up USD 0.8399, 11.73%): Momentum Versus Thin Liquidity

Cheche Group (NASDAQ:CCG) gained 11.73% to USD 8.00 in pre-market trading on November 3, 2026, implying a prior close of about USD 7.16 (calculated). No company announcement dated October 30 to November 3, 2026 was identified. The move may reflect momentum, thin liquidity or positioning around earlier news, but that is not confirmed.

First-half 2026 net revenues fell 34.4% to RMB 885.0 million, and net loss widened 72.3% to RMB 44.1 million. A non-binding term sheet from September 9, 2026 values Long Way Fortune at an implied USD 490 million. A 35-for-1 consolidation took effect on July 20, 2026, and about 2.51 million shares outstanding per a data page suggests a very small float.

SurgePays (NASDAQ:SURG) (up USD 0.0132, 8.57%): A Bounce in a Sub-Dollar Penny Stock

SurgePays (NASDAQ:SURG) advanced 8.57% to USD 0.1672 in pre-market trading on November 3, 2026. No announcement dated October 30 to November 3, 2026 was identified, so trading behavior is the more measured explanation. Small order flow can produce large percentage swings in a Penny Stock at this price.

Second quarter 2026 revenue was USD 16.20 million, up 40.7%, and Net Income available to common stockholders was USD 1.29 million, which included an USD 8.51 million gain on contract settlement. Cash and cash equivalents were USD 1,954,235 at June 30, 2026. A proposed smartphone rent-to-own joint venture, with SurgePays expecting 51%, was disclosed on September 3, 2026.

Where Things Stand

Each of these five companies moved on November 3, 2026 without an announcement that explains the move, and four of them trade under USD 5 as penny stocks. PAVmed (NASDAQ:PAVM) and Hain Celestial Group (NASDAQ:HAIN) have dated reporting events ahead, while Zhengye Biotechnology (NASDAQ:ZYBT), Cheche Group (NASDAQ:CCG) and SurgePays (NASDAQ:SURG) have none identified. Investors may look for filings, results, Nasdaq notices and whether Volume backs up the pre-market levels once regular trading gets underway.